PAUL HICKEY President and Chief Executive Officer Global Multi-Billion Dollar Underserved Market Executing our growth pillars will provide a path to profitability. 5 If the Lap-Band needs to be removed for any reason, it is easily reversible. 9 Fighting Obesity: A Lifelong Patient Weight Loss Journey Lifesciences. Over 25 years of executive leadership and consulting experience in medical device regulatory affairs, clinical research, compliance, and reimbursement. Zoey ReShaped since 2018 Expanded gastric ca ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q4 2022 Earnings Conference Call April 25, 2023 4:30 PM ET Company Participants Michael Miller - Investor Relations Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon, and thank you for joining the ReShape Lifesciences' Year-End 2022 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. Please go ahead. ...

| | | For the fiscal year ended December 31, 2022 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol Name of Each Exchange on which Registered C ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Paula Schwartz - Managing Director-Rx Communications Group Paul Hickey - President & Chief Executive Officer Thomas Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Ben Haynor - AGP Operator Good morning and thank you for joining the ReShape Lifesciences Third Quarter 2022 Conference Call. I would now like to turn the call over to Paula Schwartz ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. Indicate by check mark whether the registrant (1) has filed all reports required to be file ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Michael Miller - Rx Communications, Investor Relations Paul Hickey - President and Chief Executive Officer Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group Operator Good afternoon. Thank you for joining the ReShape Lifesciences Second Quarter 2022 Conference Call. I would like to turn the call over to Michael Miller from Rx Communication ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2022 Earnings Conference Call May 23, 2022 8:30 AM ET Company Participants Michael Miller - Rx Communications, Investor Relations Bart Bandy - President and Chief Executive Officer Tom Stankovich - Chief Financial Officer Conference Call Participants Operator Good day and thank you for standing by. Welcome to the ReShape Lifesciences First Quarter 2022 Earnings Webcast. I would now like to hand the conference over to Michael Miller of Rx Communications. Please go a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or ...